Brave patient in the pediatrician’s office – prevention and therapy of influenza Review article
Article Sidebar
Published:
Dec 31, 2023
Keywords:
influenza, children, therapy, oseltamivir
Main Article Content
Abstract
The strategy of fighting influenza is based on infection prevention based on the vaccination program on the one hand, and on early diagnosis of infection and implementation of therapy on the other. A third option that is gaining in importance is the prophylactic inclusion of oseltamivir after contact with an infected patient. Due to the lower effectiveness of vaccinations, the use of oseltamivir is particularly important in infants and young children.
Article Details
How to Cite
Sapilak , B. J. (2023). Brave patient in the pediatrician’s office – prevention and therapy of influenza. Medycyna Faktow (J EBM), 16(4(61), 353-356. https://doi.org/10.24292/01.MF.0423.10
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Profilaktyka i leczenie grypy. Wytyczne Kolegium Lekarzy Rodzinnych w Polsce (2019). Kolegium Lekarzy Rodzinnych w Polsce, Kraków 2019.
2. Wytyczne Światowej Organizacji Zdrowia dotyczące postępowania w przypadku grypy [access: 30.04.2020].
3. Malosh RE, Martin ET, Heikkinen T et al. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis. 2018; 66(10): 1492-500.
4. Butler CC, van der Velden AW, Bongard E et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020; 395(10217): 42-52. http://doi.org/10.1016/S0140-6736(19)32982-4.
5. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low-and high-risk patients. J Antimicrob Chemother. 2010; 65(suppl 2): ii11-ii24. http://doi.org/10.1093/jac/dkq012.
6. Matsuzaki Y, Mizuta K, Aoki Y et al. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J. 2010; 7: 53. http://doi.org/10.1186/1743-422X-7-53.
2. Wytyczne Światowej Organizacji Zdrowia dotyczące postępowania w przypadku grypy [access: 30.04.2020].
3. Malosh RE, Martin ET, Heikkinen T et al. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis. 2018; 66(10): 1492-500.
4. Butler CC, van der Velden AW, Bongard E et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020; 395(10217): 42-52. http://doi.org/10.1016/S0140-6736(19)32982-4.
5. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low-and high-risk patients. J Antimicrob Chemother. 2010; 65(suppl 2): ii11-ii24. http://doi.org/10.1093/jac/dkq012.
6. Matsuzaki Y, Mizuta K, Aoki Y et al. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J. 2010; 7: 53. http://doi.org/10.1186/1743-422X-7-53.